



The Nifty ended 0.95% up at 15,582.80. It opened on a positive note and continued moving higher towards ending with a bullish body candle. Chart pattern suggests, 15300 may now act as the short-term base support. However, index majors not moving in tandem with the Nifty is a concern. Hence, staying cautious on rise is advised. 15,600-15,650 is the thick resistance.

On the Nifty hourly chart; both the leading indicators are hovering in the overbought zone. Hence, staying cautious on rise advised.

Nifty patterns on multiple time frames suggest; Ending the day above critical resistance placed around 15300 is an extremely positive development. However, don't rule out the possibility of minor retracement. Probable trading range is likely to be 15,300-15,650.

Nifty Crucial Supports & Resistances-

Supports- 15300, 15200 Resistances- 15600, 15650

Open Positional Calls-

T+3 Positional Buy-
|Cash Segment| PFC @ 117-116,
TGT- 124, Closing SL- 112

T+3 Positional Buy-
|Cash Segment| NMDC on dips
around @ 181-180, TGT- 190, SL-
closing below 175

T+3 Positional Buy-
|Cash Segment| M&M FIN on dips
around @ 158-157, TGT- 167, SL-
closing below 152

T+10 Positional Buy-
|Cash Segment| EXIDE on dips
around @ 192-190, TGT- 210, SL-
closing below 180

T+2 Positional Buy-
|Cash Segment| MOTHER SUMI @
240-239, TGT- 247, Closing SL- 235

Key Contents	Page No.
Concall update	4
Result Update	6
Domestic News	7

Nifty Intraday Chart



Market in Retrospect

India's stocks gained, with a key benchmark posting another record close, led by Reliance Industries Ltd. even as investors await the release of the country's economic growth data for the fiscal year ended March later today.

Nifty index ended 0.95% higher at 15,583. The broader markets represented by the NIFTY 500 Index ended 0.83% higher, ending at 13,226. Among the sectorial indices, NIFTY Metal was the top gainer, gaining by 2.10%, followed by NIFTY Energy, gaining by 1.75% higher. NIFTY Media was the top loser, losing by 1.36%

RIL was the top gainer, gaining by 3.13%, followed by ICICI Bank and JSW Steel which gained by 3.06% & 3.06% respectively. M&M was the top loser, losing by 4.48%, followed by Adani Ports & SE and L&T which fell by 0.85% & 0.70% respectively.

The Advance : Decline ratio stood at 1094:882

Market Turnover (In Crore) 31-05-2021

Name	Last	Previous
NSE Cash	*NA	74124.86
NSE F&O	3079549.69	2288107.33
BSE Cash	5,316.21	5,386.62
BSE F&O	*NA	24.48

FII Derivatives Flow (In Crore) 28-05-2021*

Instrument	Purchase	Sale	Net
Index Future	3460.39	3022.68	437.71
Index Option	230505.76	228818.46	1687.3
Stock Future	12863.38	13838.83	975.45
Stock Option	11574.21	12187.41	613.2

Institutional Flow (In Crore) 28-05-2021*

Institution	Purchase	Sale	Net
FII	5917.71	5004.12	913.59
DII	6440.88	5165.66	1275.22

*Data not updated till 5:30pm

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
RIL	3.13	8.80	27285782	10531550
ICICI Bank	3.06	2.38	21786138	17447160
JSW Steel	3.06	4.32	11685565	18184430
Dr. Reddy'S Lab	2.21	0.70	867648	712546
Bharti Airtel	2.16	1.54	12567516	10942560

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
IOCL	0.55	0.18	18219003	45096150
Indusind Bank	0.62	0.82	2643491	4551638
Larsen & Toubro	0.70	1.69	2405318	3444296
Adani Ports & SE	0.85	0.39	7820165	8398741
M&M	4.48	0.25	17596018	6033051

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	51937.44	514.56	1.00	2.54	6.47	5.78	60.18
Nifty	15582.80	147.15	0.95	2.53	6.50	7.25	62.65
BSE M Cap	21758.39	96.56	0.45	0.41	7.12	8.91	83.72
BSE S Cap	23595.98	117.29	0.50	1.31	8.89	17.07	116.62
Nifty MC 100	25775.45	80.35	0.31	0.75	6.53	10.77	94.19
BSE Auto	23541.12	31.28	0.13	1.55	8.65	2.63	67.02
BSE Capgoods	22498.27	21.37	0.10	0.50	11.09	4.55	82.41
BSE FMCG	13130.73	135.01	1.04	1.74	4.97	9.73	20.49
BSE Metal	18877.33	415.85	2.25	1.87	5.92	37.60	177.39
BSE Oil&Gas	16472.31	221.22	1.36	2.48	9.85	5.98	39.17
BSE Healthcare	24534.98	117.54	0.48	0.29	4.27	17.64	56.81
BSE Power	2816.44	33.60	1.21	2.16	13.51	16.44	90.10
BSE Realty	2680.01	35.10	1.33	3.54	8.58	3.84	89.88
BSE ConsDur	33389.27	228.78	0.69	2.44	3.29	5.14	76.04
BSE Bank	40344.68	481.20	1.21	1.81	8.15	3.50	82.26
BSE IT	27584.81	42.50	0.15	3.25	4.86	12.94	96.09

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.59	0.00	0.00	0.43	1.94	13.48	144.30
UK	0.80	0.02	1.85	4.22	0.25	3.05	278.57
Brazil	3.75	0.03	0.69	2.98	6.51	4.44	25.15
Japan	0.09	0.00	4.82	8.75	10.31	46.30	1640.00
Australia	1.71	0.02	1.30	0.71	2.01	10.75	93.33
India	6.02	0.02	0.32	0.84	0.13	3.39	4.51
Switzerland	0.14	0.00	1.37	2.04	28.00	25.77	68.97
Germany	0.16	0.02	12.02	15.00	20.30	38.08	63.98

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	72.62	0.17	0.23	0.48	2.03	1.29	4.04
USD Index	90.07	0.04	0.04	0.25	1.33	0.89	8.41
YUAN	6.37	0.00	0.05	0.75	1.62	1.48	11.87
GBP	1.42	0.00	0.10	0.12	2.55	1.79	13.46
EUR	1.22	0.00	0.02	0.21	1.41	1.17	9.46
YEN	109.68	0.17	0.16	0.85	0.34	2.66	1.91

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2596.00	92.00	3.42	9.52	14.97	54.99	415.08
Baltic Dirty	604.00	1.00	0.17	1.79	0.33	9.72	15.29
SG Dubai HY	0.80	0.68	566.67	5.26	44.44	38.93	157.55

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34529.45	64.81	0.19	0.94	1.93	11.63	36.03
Nasdaq	13748.74	12.46	0.09	2.06	1.53	4.22	44.88
S&P 500	4204.11	3.23	0.08	1.16	0.55	10.31	38.10
FTSE100	7022.61	2.94	0.04	0.06	0.76	8.32	15.57
CAC40	6484.50	0.39	0.01	1.19	3.43	13.70	38.10
DAX	15487.77	33.56	0.22	0.32	2.32	12.33	33.66
Mexico IPC	50040.75	412.79	0.83	0.53	4.23	12.22	38.53
Brazil Bovespa	125561.4	1194.80	0.96	2.42	5.61	14.11	43.66
Russian RTS	1598.94	4.71	0.29	1.79	7.68	13.25	31.10
Japan Nikkei	28860.08	289.33	0.99	1.75	0.16	0.37	31.91
Hang Seng	29151.80	27.39	0.09	2.60	1.49	0.59	26.96
Taiwan Index	17068.43	197.57	1.17	4.47	2.84	6.99	55.99
Shanghai Comp	3615.48	14.69	0.41	3.38	4.89	3.03	26.75
KOSPI	3203.92	15.19	0.48	1.90	1.78	6.34	57.86
Malaysia KLCI	1583.55	10.89	0.68	1.37	1.13	0.37	7.49
Jakarta Comp	5947.47	98.85	1.69	3.02	0.80	4.72	25.11
Philippine SE	6628.49	46.02	0.69	7.52	4.04	2.45	13.52
Thai Exch	1593.59	11.61	0.73	2.65	0.66	6.47	18.67

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	66.99	0.66	1.00	1.41	5.35	8.91	88.73
BRENT Crude	69.39	0.67	0.97	1.49	4.69	11.11	63.73
Natural Gas	3.02	0.04	1.21	2.09	1.48	3.53	17.45

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1904.90	1.02	0.05	1.26	7.67	9.85	10.09
Silver(\$/Ounce)	27.96	0.01	0.04	0.64	7.83	4.80	56.43
Aluminium	2458.51	7.26	0.30	5.08	2.67	14.39	62.34
Copper	10248.25	43.10	0.42	3.86	3.72	12.13	93.16
Zinc	3043.55	0.45	0.01	2.87	4.84	9.66	56.88
Lead	2196.25	12.50	0.57	0.13	5.56	7.73	36.12

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	162.35	7.00	4.51	8.16	11.31	16.55	49.91
Cotton	83.32	0.14	0.17	0.12	3.20	1.20	42.48
Sugar	17.36	0.24	1.40	4.14	1.28	9.53	51.48
Wheat	663.50	12.75	1.89	1.59	8.20	2.08	23.73
Soybean	1530.50	6.50	0.42	0.28	1.11	9.99	77.35

Fortis Healthcare Ltd.

Hospital Business

- Towards the end of May, encouraging signs of receding Covid cases are being witnessed. Elective surgeries on the other hand are accelerating.
- In Q4FY21, there was an increase in elective surgeries. Non Covid occupancy was around 57%. Covid occupancy was between 25-30% in April and non Covid saw 40% occupancy. Overall occupancy was between 68-70% in April. Covid ARPOB is around Rs 10 mln. Non Covid ARPOB in Q4FY21 was around Rs 18 mln and in Q1FY22 it is expected to be around Rs 17 mln. The non Covid ARPOB figure is sustainable for the full year FY22.
- Current operational beds stand at around 3900.
- Strategic cost reduction/optimisation exercises are still on such as on the pharmacy procurement side. Voluntary salary reductions that were taken during Q1 and Q2FY21 were rolled back from Q3FY21 onwards.
- Eminent clinicians across specialities were added in Q4FY21 and will continue to get added in the future.
- The second wave is distinctly different from the first wave as overall occupancy is not dropping to a high degree as was seen during Q1 and Q2FY21. In fact, overall occupancies are now static with reduction in non Covid occupancies being balanced by growth in Covid occupancies.
- Hospital Business is now well poised for growth with plans of adding 1300 beds in the next 2-3 years. The total costs for this expansion including cost of Arcot Road facility would be around Rs 8000-9000 mln. Inorganic expansion opportunities would also be considered after 2-3 months. Inorganic opportunities will be considered in existing areas of presence.
- There are definite levers to move up the Hospital EBITDA margin from the current level of around 17%. These include cost control measures, improvement in payor mix, rebound in international business and improvement of underperforming assets.
- Currently 6 lakhs doses of vaccines are administered each month across Fortis Hospitals. This number can easily double to 12 lakhs doses if supply constraints are alleviated. Net administration charges of Rs 150-300 less 25% cost of labour charges, etc. are accruing in the Hospital P&L. However, full average collection from customers per dose of around Rs 1000 per dose is booked as revenue in the Hospital P&L. Vaccination revenue is expected to accrue at least till December 2021.

Diagnostics Business/SRL

- Q4FY21 was the second consecutive quarter of Rs 3,000 mln revenue for SRL.
- In the last 9 months, SRL's revenue grew by 18% YoY and EBITDA by 48% YoY. There was a 10% growth in non Covid revenue in Q4FY21 against Q4FY20. Preventive check-ups witnessed a growth of 28% YoY in Q4FY21.
- The digital initiatives are paying off – there are more than 3 million users who have signed up on the SRL mobile app.

- Home collection facility has been extended to 90 cities now. In Q4FY21 70% of home visits were related with non Covid tests.
- 128 collection centres were added in Q4FY21. 5 more labs with RTPCR facility will be added by the end of Q1FY22 – these would focus more on diagnosing samples collected from rural areas.
- Post the DDRC acquisition, SRL has become the largest player in South India. DDRC turnover in FY21 was around Rs 3,030 mln. EBITDA margin was around 21%.
- SRL aspires to make a normalised EBITDA margin of around 28% (similar to that of peers) in 2-3 years' time. SRL today has the largest number of labs in its network compared to all its peers and it's just a question of improving the utilisation of these labs.
- B2C business should improve further to 48-50% in FY22.

Others

- If the judgement is in favour of IHH in the Supreme Court case, the cost of borrowings should at least come down by 50 bps from the current level of 7.5% as rating of Fortis would improve. Judgement is expected in July when the court resumes operation post summer vacation.

Dollar Industries Ltd.

Q4FY21- Standalone-

- Company's Net sales increased by 29.9% on YoY basis to INR3,083.1 mn.
- Q4FY21 Gross margin increased by 625 bps on YoY basis to 34.9%.
- Q4FY21 EBITDA increased by 48.3% YoY to 311.2 mn. Q4FY21 EBITDA margin increased by 125 bps YoY to 10.1%.
- Q4FY21 PAT increased by 50.9% YoY to INR201 mn.
- EPS 3.54 vs 2.35 YoY

FY21- Standalone-

- Company's Net sales increased by 7.2% on YoY basis to INR10,370 mn.
- FY21 Gross margin increased by 229 bps YoY to 36.7%.
- FY21 EBITDA increased by 32% YoY to 1,380.8 mn. FY21 EBITDA margin increased by 250 bps to 13.3%.
- FY21 PAT increased by 47% YoY to INR872.8 mn
- EPS 15.39 vs 10.48 YoY
- The Board has recommended a dividend of INR2.40/- per equity share of INR2 each for the year ended 31st March, 2021.

Aurobindo Pharma

Aurobindo Pharma reported a consolidated net profit of INR801.18 crore for the fourth quarter ended March 2021. The company had posted a net profit of INR863.16 crore for the corresponding period of the previous fiscal. Its consolidated revenue from operations stood at INR6,001.50 crore for the quarter under consideration. It was INR6,158.43 crore a year ago. For the fiscal ended March this year, the company posted a net profit of INR5,333.83 crore. It was INR2,843.67 crore in the preceding fiscal year. The company's revenue from operations stood at INR24,774.63 crore for 2020-21. It was INR23,098.50 crore in the previous fiscal.

Shilpa Medicare

Net profit of Shilpa Medicare declined 77.35% to INR7.83 crore in the quarter ended March 2021 as against INR34.57 crore during the previous quarter ended March 2020. Sales declined 5.44% to INR208.03 crore in the quarter ended March 2021 as against INR219.99 crore during the previous quarter ended March 2020. For the full year, net profit declined 5.36% to INR147.78 crore in the year ended March 2021 as against INR156.15 crore during the previous year ended March 2020. Sales declined 0.75% to INR901.13 crore in the year ended March 2021 as against INR907.91 crore during the previous year ended March 2020.

Construction firm J Kumar Infraprojects bags INR1,307.8 cr order from MMRDA

J Kumar Infraprojects Ltd has bagged an order worth INR1,307.88 crore from the Mumbai Metropolitan Region Development Authority. The company said the order is for part design and construction of balance works of Mumbai Metro Rail project. The company has received a letter of acceptance from Mumbai Metropolitan Region Development Authority (MMRDA) for part design and construction of balance works of Mumbai Metro Rail project of MMRDA, amounting to INR1,307.88 crore.

Petrol prices continue to soar above INR100 in Mumbai, Bhopal

Fuel prices have touched an all-time high after Monday's fresh hike. Petrol continued to cost more than INR100 in parts of Mumbai and Bhopal. Petrol in Mumbai stood at INR100.47 per litre and diesel at INR92.45 per litre. In Madhya Pradesh's Bhopal, the petrol price stood at INR102.34 per litre while diesel stood at INR93.37 per litre. Meanwhile, petrol and diesel prices witnessed a minor surge in the national capital and stood at INR94.23 and INR85.15 per litre, respectively. The petrol prices were increased by 29 paise per litre and diesel by 26 paise in Delhi. In Kolkata, the prices of petrol stood at INR94.25 and diesel at INR87.74.

JB Chemicals launches medicated nicotine lozenges to help quit smoking

J B Chemicals & Pharmaceuticals has launched medicated nicotine lozenges that will help reduce the urge to consume or smoke tobacco. On the occasion of 'World No Tobacco Day', the drug maker has also launched an Artificial Intelligence-enabled chatbot 'Dr Will', which would encourage and support tobacco smokers to quit smoking. The medicated nicotine lozenges will be available in mint flavour as sugar-based and sugar-free variants in 2mg and 4mg strengths.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
India Grid Trust	Cash dividend of INR3.10 effective 01-06-2021
HDFC Bank Ltd	Corporate meeting effective 01-06-2021
Majestic Research Services and Solutions Ltd	Corporate meeting effective 01-06-2021

Domestic Events

- **Upcoming Result's:-** Balrampur Chini Mills Ltd., Gujarat Gas Ltd., ITC Ltd., Radico Khaitan Ltd., Motherson Sumi Systems Ltd., Muthoot Finance Ltd., PVR Ltd.
- India Markit Manufacturing PMI for May 2021.
- India Trade Balance for May 2021.

Global Events

- China Caixin Manufacturing PMI for May 2021.
- Japan Jibun Bank Manufacturing PMI for May 2021.
- Euro Area Markit Manufacturing PMI for May 2021.
- Euro Area Unemployment Rate for April 2021.
- Euro Area Inflation for May 2021.
- The U.S. Manufacturing PMI for May 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com